{"url_path":"/sec/srpt/8-k/2026-06-04/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/873303/0001193125-26-257501-index.html","accession_number":"0001193125-26-257501","cik":"0000873303","ticker":"SRPT","issuer_name":"Sarepta Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/873303/0001193125-26-257501-index.html","primary_entity_key":"0000873303","primary_entity_name":"Sarepta Therapeutics, Inc."},"word_count":94,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNumber\n  \nDescription\n\n10.1\n  \n[2026 Equity Incentive Plan](d88936dex101.htm)\n\n10.2\n  \n[2026 Employee Stock Purchase Plan](d88936dex102.htm)\n\n104\n  \nThe cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nSarepta Therapeutics, Inc.\n\nDate:June 4, 2026\n \n\n \nBy:\n \n\n/s/ Douglas S. Ingram\n\n \n\n \n\n \nDouglas S. Ingram\n\n \n\n \n\n \nChief Executive Officer"}